

LEGISLATURE OF THE STATE OF IDAHO
Sixty-first Legislature First Regular Session - 2011

IN THE HOUSE OF REPRESENTATIVES

HOUSE BILL NO. 139

BY JUDICIARY, RULES, AND ADMINISTRATION COMMITTEE

AN ACT

RELATING TO UNIFORM CONTROLLED SUBSTANCES; AMENDING SECTION 37-2705, IDAHO CODE, TO IDENTIFY ADDITIONAL SUBSTANCES TO BE CLASSIFIED IN SCHEDULE I; AND DECLARING AN EMERGENCY.

Be It Enacted by the Legislature of the State of Idaho:

SECTION 1. That Section 37-2705, Idaho Code, be, and the same is hereby amended to read as follows:

37-2705. SCHEDULE I. (a) The controlled substances listed in this section are included in schedule I.

(b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

- (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
- (2) Acetylmethadol;
- (3) Allylprodine;
- (4) Alphacetylmethadol (except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol, levomethadyl acetate or LAAM);
- (5) Alphameprodine;
- (6) Alphamethadol;
- (7) Alpha-methylfentanyl;
- (8) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- (9) Benzethidine;
- (10) Betacetylmethadol;
- (11) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);
- (12) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide);
- (13) Betameprodine;
- (14) Betamethadol;
- (15) Betaprodine;
- (16) Clonitazene;
- (17) Dextromoramide;
- (18) Diampromide;
- (19) Diethylthiambutene;
- (20) Difenoxin;
- (21) Dimenoxadol;
- (22) Dimepheptanol;
- (23) Dimethylthiambutene;
- (24) Dioxaphetyl butyrate;

- 1 (25) Dipipanone;
- 2 (26) Ethylmethylthiambutene;
- 3 (27) Etonitazene;
- 4 (28) Etoxeridine;
- 5 (29) Furethidine;
- 6 (30) Hydroxypethidine;
- 7 (31) Ketobemidone;
- 8 (32) Levomoramide;
- 9 (33) Levophenacymorphan;
- 10 (34) 3-Methylfentanyl;
- 11 (35) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-pip-
- 12 eridiny]l)-N-phenylpropanamide);
- 13 (36) Morpheridine;
- 14 (37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 15 (38) Noracymethadol;
- 16 (39) Norlevorphanol;
- 17 (40) Normethadone;
- 18 (41) Norpipanone;
- 19 (42) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-
- 20 piperidiny]l propanamide);
- 21 (43) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 22 (44) Phenadoxone;
- 23 (45) Phenampromide;
- 24 (46) Phenomorphan;
- 25 (47) Phenoperidine;
- 26 (48) Piritramide;
- 27 (49) Proheptazine;
- 28 (50) Properidine;
- 29 (51) Propiram;
- 30 (52) Racemoramide;
- 31 (53) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidiny]l)-
- 32 propanamide);
- 33 (54) Tilidine;
- 34 (55) Trimeperidine.

35 (c) Any of the following opium derivatives, their salts, isomers and
 36 salts of isomers, unless specifically excepted, whenever the existence of
 37 these salts, isomers and salts of isomers is possible within the specific
 38 chemical designation:

- 39 (1) Acetorphine;
- 40 (2) Acetyldihydrocodeine;
- 41 (3) Benzylmorphine;
- 42 (4) Codeine methylbromide;
- 43 (5) Codeine-N-Oxide;
- 44 (6) Cyprenorphine;
- 45 (7) Desomorphine;
- 46 (8) Dihydromorphine;
- 47 (9) Drotebanol;
- 48 (10) Etorphine (except hydrochloride salt);
- 49 (11) Heroin;
- 50 (12) Hydromorphanol;

- 1 (13) Methyldesorphine;
- 2 (14) Methyldihydromorphine;
- 3 (15) Morphine methylbromide;
- 4 (16) Morphine methylsulfonate;
- 5 (17) Morphine-N-Oxide;
- 6 (18) Myrophine;
- 7 (19) Nicocodeine;
- 8 (20) Nicomorphine;
- 9 (21) Normorphine;
- 10 (22) Pholcodine;
- 11 (23) Thebacon.

12 (d) Hallucinogenic substances. Any material, compound, mixture or
 13 preparation which contains any quantity of the following hallucinogenic
 14 substances, their salts, isomers and salts of isomers, unless specifically
 15 excepted, whenever the existence of these salts, isomers, and salts of iso-
 16 mers is possible within the specific chemical designation (for purposes of
 17 this paragraph only, the term "isomer" includes the optical, position and
 18 geometric isomers):

- 19 (1) 4-bromo-2,5-dimethoxy amphetamine;
- 20 (2) 2,5-dimethoxyamphetamine;
- 21 (3) 4-bromo-2,5-dimethoxyphenethylamine (some other names: alp-
 22 ha-desmethyl DOB, 2C-B);
- 23 (4) 2,5-dimethoxy-4-ethylamphetamine (another name: DOET);
- 24 (5) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- 25 (6) 4-methoxyamphetamine (PMA);
- 26 (7) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 27 (8) 5-methoxy-N,N-diisopropyltryptamine;
- 28 (9) 4-methyl-2,5-dimethoxy-amphetamine (DOM, STP);
- 29 (10) 3,4-methylenedioxy amphetamine;
- 30 (11) 3,4-methylenedioxymethamphetamine (MDMA);
- 31 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known as N-et-
 32 hyl-alpha-methyl-3,4 (methylenedioxy) phenethylamine, and N-et-
 33 hyl MDA, MDE, MDEA);
- 34 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hyd-
 35 roxy-alpha-methyl-3,4 (methylenedioxy) phenethylamine, and N-hyd-
 36 roxy MDA);
- 37 (14) 3,4,5-trimethoxy amphetamine;
- 38 (15) Alpha-ethyltryptamine (some other names: etryptamine, 3-(2-am-
 39 inobutyl) indole);
- 40 (16) Alpha-methyltryptamine;
- 41 (17) Bufotenine;
- 42 (18) Diethyltryptamine (DET);
- 43 (19) Dimethyltryptamine (DMT);
- 44 (20) Ibogaine;
- 45 (21) Lysergic acid diethylamide;
- 46 (22) Marihuana;
- 47 (23) Mescaline;
- 48 (24) Parahexyl;
- 49 (25) Peyote;
- 50 (26) N-ethyl-3-piperidyl benzilate;

(27) N-methyl-3-piperidyl benzilate;

(28) Psilocybin;

(29) Psilocyn;

(30) Tetrahydrocannabinols- or sSynthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity such as the following:

i. Tetrahydrocannabinols:

a. Δ^1 cis or trans tetrahydrocannabinol, and their optical isomers, excluding dronabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the U.S. Food and Drug Administration.

b. Δ^6 cis or trans tetrahydrocannabinol, and their optical isomers.

c. $\Delta^{3,4}$ cis or trans tetrahydrocannabinol, and its optical isomers. (Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions are covered.)

d. [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2methyl-octan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol)], also known as 6aR-trans-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol (HU-210) and it's geometric isomers (HU211 or dexanabinol).

ii. The following synthetic drugs:

a. Any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the naphthyl ring to any extent.

b. Any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent.

c. Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent.

d. Any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the

indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent.

e. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not substituted in the cyclohexyl ring to any extent.

f. Any compound structurally derived from 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

g. [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrol-o[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone (WIN-55,212-2).

h. 3-dimethylheptyl-11-hydroxyhexahydrocannabinol (HU-243).

i. 9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate (CP 50,5561).

(31) Ethylamine analog of phencyclidine (N-ethyl-1-phenylcyclohexylamine (1-phenylcyclohexyl) ethylamine; N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;

(32) Pyrrolidine analog of phencyclidine: 1-(phenylcyclohexyl) - pyrrolidine, PCPy, PHP;

(33) Thiophene analog of phencyclidine 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP;

(34) 1-[1-(2-thienyl) cyclohexyl] pyrrolidine another name: TCPy;

(35) Spores or mycelium capable of producing mushrooms that contain psilocybin or psilocin.

(e) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Gamma hydroxybutyric acid (some other names include GHB; gamma-hydroxybutyrate, 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);

(2) Flunitrazepam (also known as "R2," "Rohypnol");

(3) Mecloqualone;

(4) Methaqualone.

(f) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on

the central nervous system, including its salts, isomers, and salts of isomers:

- (1) Aminorex (some other names: aminoxaphen, 2-amino-5-phenyl-2-oxazoline, or 4,5-dihydro-5-phenyl-2-oxazamine);
 - (2) Cathinone (some other names: alpha-aminopropiophenone, 2-amino-propiophenone and norephedrone);
 - (3) Fenethylamine;
 - (4) Methcathinone (some other names: 2-(methyl-amino)-propiophenone, alpha-(methylamino)-propiophenone, N-methylcathinone, AL-464, AL-422, AL-463 and UR1423);
 - (5) (+/-)cis-4-methylaminorex [(+/-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazamine];
 - (6) N-benzylpiperazine (also known as: BZP, 1-benzylpiperazine);
 - (7) N-ethylamphetamine;
 - (8) N,N-dimethylamphetamine (also known as: N,N-alpha-trimethyl-benzeneethanamine).
 - (g) Temporary listing of substances subject to emergency scheduling.
- Any material, compound, mixture or preparation which contains any quantity of the following substances:
- (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts and salts of isomers.
 - (2) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its optical isomers, salts and salts of isomers.

SECTION 2. An emergency existing therefor, which emergency is hereby declared to exist, this act shall be in full force and effect on and after its passage and approval.